Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.

McNicholas P, Wei Y, Whitcomb J, Greaves W, Black TA, Tremblay CL, Strizki JM.

J Infect Dis. 2010 May 15;201(10):1470-80. doi: 10.1086/652189.

PMID:
20373959
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.

Klibanov OM.

Curr Opin Investig Drugs. 2009 Aug;10(8):845-59. Review.

PMID:
19649929
4.

Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.

Lenz JC, Rockstroh JK.

Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1139-50. doi: 10.1517/17425255.2010.510833. Review.

PMID:
20712521
5.

Genotypic resistance tests for the clinical management of patients with primary HIV infection.

Narciso P, Lazzarin A.

Scand J Infect Dis Suppl. 2003;106:66-70. Review.

PMID:
15000588
6.

Genotypic coreceptor analysis.

Sierra S, Kaiser R, Thielen A, Lengauer T.

Eur J Med Res. 2007 Oct 15;12(9):453-62. Review.

PMID:
17933727
7.

Supplemental Content

Support Center